Laureate To Manufacture for ImmunoGen

Laureate Pharma, Inc. has entered into a contract manufacturing agreement with ImmunoGen, Inc. to manufacture the huC242 antibody used in production of ImmunoGen’s huC242-DM4 Tumor-Activated Prodrug (TAP) compound, now in Phase II clinical testing. Terms of the manufacturing agreement were not disclosed.

“ImmunoGen is well known for its proprietary TAP technology, which uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells,” noted Robert J. Broeze, Ph.D., president and chief executive officer of Laureate Pharma. “Laureate Pharma has an established track record in the manufacture of protein based biopharmaceuticals. We are pleased that ImmunoGen chose us to manufacture their antibody and we are excited to be working with them.”